Business Description
Karyopharm Therapeutics is a Massachusetts-based pharmaceutical company focused on developing cancer treatments that work by blocking a specific protein responsible for moving molecules out of cell nuclei. Its flagship drug, XPOVIO, is approved to treat several forms of blood cancer, including multiple myeloma and a type of aggressive lymphoma. The company is also advancing additional compounds targeting a broader range of blood and solid tumor cancers, while partnering with other pharmaceutical firms across Europe and Asia to expand the global reach of its medicines.
